A daily pill given with chemotherapy shrank or cleared tumours in more than six in ten patients with metastatic pancreatic cancer, in results specialists are calling the biggest advance in the disease for decades. In about one in twelve patients, scans showed no sign of the cancer at all. But the doctors behind the work are careful to say the treatment is not a cure — and the trial had no control group, so the results still need testing in a larger, randomised study.

Daraxonrasib was given with chemotherapy to 61 people whose pancreatic cancer had recently been diagnosed and had already spread beyond the pancreas. Tumours shrank significantly or became undetectable in 60.7% of them, and 8.2% achieved a complete response — no evidence of the tumour on scans. Tumours stopped growing in 90.2% of patients, and 76.6% were still alive after 12 months, against about 25% on standard treatment.

“This is the biggest leap forward we've seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers.”— Michelle Mitchell, Cancer Research UK chief executive

The Details

The results come from the phase I/II RMC-GI-102 trial, presented by lead researcher Dr. Wungki Park of Memorial Sloan Kettering Cancer Center in Barcelona. The patients had previously untreated metastatic pancreatic cancer.

Patients took daraxonrasib, 200 mg daily, plus two standard chemotherapy drugs — gemcitabine and nab-paclitaxel — on days 1 and 15 of each cycle. The median follow-up was 18.3 months. The median time before tumours started growing again was 12.8 months — nearly double the five to six months on standard chemotherapy.

Daraxonrasib locks onto the mutated KRAS gene, found in more than nine in ten pancreatic tumours, which continuously signals cancer cells to grow. The drug was developed with the Dana-Farber Cancer Institute and Revolution Medicines, and was approved by the US Food and Drug Administration in August 2026 under the brand name Rasonque as a single-agent treatment. In this trial it was used for the first time as a first-line combination with chemotherapy.

Side effects — rash, diarrhoea, fatigue and low blood cell counts — were managed with standard care, and only 5% stopped daraxonrasib because of them.

How We Got Here

Pancreatic cancer is one of the deadliest common cancers. More than half of patients are diagnosed only after the disease has already spread. Standard chemotherapy shrinks tumours in only 23% to 42% of patients, and the disease usually starts growing again within months. Median survival on standard treatment is eight to eleven months, and only about 3% are alive after five years.

Targeting the RAS gene has long been seen as the key, and long been considered chemically near-impossible. More than 90% of pancreatic cancers carry a RAS mutation, which acts like a molecular switch locked in the "on" position, telling cells to divide. Daraxonrasib was engineered to bind to the active form of the protein and shut down the signals the cancer depends on.

An earlier study, reported in May, found daraxonrasib almost doubled progression-free survival against chemotherapy alone. The new results go further: they test the drug from the start, combined with chemotherapy, in patients who have not yet had systemic treatment.

Why It Matters

Cancer Research UK called the findings the biggest leap forward in decades. Dr. Sam Godfrey, from the charity, called the results "incredibly exciting" and said progress in pancreatic cancer was long overdue, after years in which treatment barely moved.

Independent experts agreed the science matters beyond pancreatic cancer. Professor Elena Garralda, chair of the symposium, said showing that active RAS mutations can be targeted is a pivotal development for pancreatic cancer and other RAS-driven cancers, including some lung and bowel cancers.

Because the trial had no randomised control arm, the results cannot be directly compared with chemotherapy by itself — the 76.6% twelve-month survival and the 12.8-month progression-free survival are set against historical benchmarks, not a group treated at the same time. The follow-up is 18 months, and nobody yet knows how long the benefit lasts.

What Happens Next

The investigators have already started the global Phase III RASolute-303 trial, led by Dr. Park, testing daraxonrasib both alone and with chemotherapy against conventional chemotherapy in a randomised group. That trial will decide whether the early signals become a proven survival benefit, and whether the treatment can be assessed for wider use. Until then, the results are a genuine reason for hope — and a reminder that hope in pancreatic cancer has been disappointed before.